Khan A, Karami S, Peidl A, Waiters K, Babajide M, Bawa-Khalfe T
Int J Mol Sci. 2024; 25(1).
PMID: 38203649
PMC: 10779387.
DOI: 10.3390/ijms25010476.
Duan C, Li K, Pan X, Wei Z, Xiao L
BMC Cancer. 2023; 23(1):489.
PMID: 37259027
PMC: 10230804.
DOI: 10.1186/s12885-023-10929-9.
Zhang H, Yin X, Zhang X, Zhou M, Xu W, Wei Z
Technol Cancer Res Treat. 2022; 21:15330338221118202.
PMID: 35929142
PMC: 9358565.
DOI: 10.1177/15330338221118202.
Skolastika S, Hanif N, Ikawati M, Hermawan A
Evid Based Complement Alternat Med. 2022; 2022:4172531.
PMID: 35845599
PMC: 9286982.
DOI: 10.1155/2022/4172531.
Zhang S, Guo S, Li Z, Li D, Zhan Q
PeerJ. 2019; 7:e7946.
PMID: 31687275
PMC: 6825748.
DOI: 10.7717/peerj.7946.
Heat shock proteins create a signature to predict the clinical outcome in breast cancer.
Klimczak M, Biecek P, Zylicz A, Zylicz M
Sci Rep. 2019; 9(1):7507.
PMID: 31101846
PMC: 6525249.
DOI: 10.1038/s41598-019-43556-1.
Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt/β-catenin signaling pathways in gastric cancer progression.
Wang H, Deng G, Ai M, Xu Z, Mou T, Yu J
Oncogene. 2018; 38(9):1489-1507.
PMID: 30305727
PMC: 6372478.
DOI: 10.1038/s41388-018-0532-5.
Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
Lee H, Saini N, Howard E, Parris A, Ma Z, Zhao Q
Sci Rep. 2018; 8(1):6829.
PMID: 29717218
PMC: 5931511.
DOI: 10.1038/s41598-018-25284-0.
Elevated levels of ribosomal proteins eL36 and eL42 control expression of Hsp90 in rhabdomyosarcoma.
Shaikho S, Dobson C, Naing T, Samanfar B, Moteshareie H, Hajikarimloo M
Translation (Austin). 2017; 4(2):e1244395.
PMID: 28090422
PMC: 5173308.
DOI: 10.1080/21690731.2016.1244395.
HSP90 Inhibitor Geldanamycin as a Radiation Response Modificator in Human Blood Cells.
Stankova K, Savova G, Nikolov V, Boteva R
Dose Response. 2015; 13(1).
PMID: 26674599
PMC: 4674165.
DOI: 10.2203/dose-response.14-039.Stankova.
Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer.
Rong B, Zhao C, Liu H, Ming Z, Cai X, Gao W
Am J Cancer Res. 2014; 4(6):874-85.
PMID: 25520875
PMC: 4266719.
Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor.
Jurczyszyn A, Zebzda A, Czepiel J, Perucki W, Bazan-Socha S, Cibor D
J Cancer. 2014; 5(6):480-90.
PMID: 24959301
PMC: 4066360.
DOI: 10.7150/jca.8731.
Heat shock protein 90 (hsp90) expression and breast cancer.
Zagouri F, Bournakis E, Koutsoukos K, Papadimitriou C
Pharmaceuticals (Basel). 2013; 5(9):1008-20.
PMID: 24280702
PMC: 3816649.
DOI: 10.3390/ph5091008.
The significance of heat shock proteins in breast cancer therapy.
Oskay Halacli S, Halacli B, Altundag K
Med Oncol. 2013; 30(2):575.
PMID: 23606238
DOI: 10.1007/s12032-013-0575-y.
Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients.
Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W
J Exp Clin Cancer Res. 2012; 31:70.
PMID: 22929401
PMC: 3444906.
DOI: 10.1186/1756-9966-31-70.
Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
Chan C, Reeves R, Geller R, Yaghoubi S, Hoehne A, Solow-Cordero D
Proc Natl Acad Sci U S A. 2012; 109(37):E2476-85.
PMID: 22895790
PMC: 3443147.
DOI: 10.1073/pnas.1205459109.
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.
Gartner E, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P
Breast Cancer Res Treat. 2011; 131(3):933-7.
PMID: 22083229
PMC: 3839045.
DOI: 10.1007/s10549-011-1866-7.
Down-regulated expression of HSP70 in correlation with clinicopathology of cholangiocarcinoma.
Boonjaraspinyo S, Boonmars T, Kaewkes S, Laummaunwai P, Pinlaor S, Loilome W
Pathol Oncol Res. 2011; 18(2):227-37.
PMID: 21750953
DOI: 10.1007/s12253-011-9432-5.
Decreased Hsp90 expression in infiltrative lobular carcinoma: an immunohistochemical study.
Zagouri F, Sergentanis T, Nonni A, Papadimitriou C, Pazaiti A, Michalopoulos N
BMC Cancer. 2010; 10:409.
PMID: 20691061
PMC: 2925828.
DOI: 10.1186/1471-2407-10-409.
Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions.
Zagouri F, Sergentanis T, Nonni A, Papadimitriou C, Michalopoulos N, Domeyer P
BMC Cancer. 2010; 10:353.
PMID: 20602789
PMC: 2912866.
DOI: 10.1186/1471-2407-10-353.